HomeSuzetrigineSuzetrigine + Sensitive Cyp3a Substrates

Does Suzetrigine Interact with Sensitive Cyp3a Substrates?

Suzetrigine and Sensitive Cyp3a Substrates have a moderate drug interaction according to U.S. FDA drug labeling data. Dosage modification of sensitive CYP3A substrates may be required when initiating or discontinuing JOURNAVX. JOURNAVX is a CYP3A inducer that may reduce exposure of CYP3A substrates. The mechanism involves suzetrigine is a cyp3a inducer that reduces exposure of sensitive cyp3a substrates. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Moderate
Suzetrigine Class
Sodium Channel Blocker
Management
Monitor for effects
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Suzetrigine and Sensitive Cyp3a Substrates occurs because suzetrigine is a cyp3a inducer that reduces exposure of sensitive cyp3a substrates. Clinically, this means dosage modification of sensitive cyp3a substrates may be required when initiating or discontinuing journavx. journavx is a cyp3a inducer that may reduce exposure of cyp3a substrates. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.

What To Tell Your Doctor or Pharmacist

If you are taking Suzetrigine and your doctor is considering prescribing Sensitive Cyp3a Substrates (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Suzetrigine(Journavx)+💊 Sensitive Cyp3a Substrates(Fluorimax Sensitive)

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
Sodium Channel Blocker
Drug B class
Source
NLP:suzetrigine

What this means in plain English

Dosage modification of sensitive CYP3A substrates may be required when initiating or discontinuing JOURNAVX. JOURNAVX is a CYP3A inducer that may reduce exposure of CYP3A substrates.

About Suzetrigine and Sensitive Cyp3a Substrates

Suzetrigine is a Sodium Channel Blocker. Suzetrigine is also sold under the brand name Journavx. Suzetrigine is taken by mouth.

What the FDA label says

"Suzetrigine is a CYP3A inducer that reduces exposure of sensitive CYP3A substrates"

📖 Source: NLP:suzetrigine

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Suzetrigine and Sensitive Cyp3a Substrates against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.